Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients

[1] Kahn SE(2006)Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427-43

[2] Haffner SM(2007)Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm Int J Clin Pract 61 (Suppl 154) 3-11

[3] Heise MA(2007)The physiology of glucagon-like peptide 1 Physiol Rev 87 1409-39

[4] Herman WH(2000)Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 43 1664-9

[5] Holman RR(2002)The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 195-202

[6] Jones NP(2013)Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study Diabetes Obes Metab 15 204-12

[7] Green J(2011)Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial Diabetes Obes Metab 13 81-8

[8] Feinglos M(2014)Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial Diabetes Care 37 1797-805

[9] Holst JJ(2013)Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus Intern Med 52 1029-34

[10] Knudsen LB(2014)Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin Eur J Endocrinol 170 451-9

[1] Kahn SE(2006)Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427-43

[2] Haffner SM(2007)Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm Int J Clin Pract 61 (Suppl 154) 3-11

[3] Heise MA(2007)The physiology of glucagon-like peptide 1 Physiol Rev 87 1409-39

[4] Herman WH(2000)Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 43 1664-9

[5] Holman RR(2002)The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 195-202

[6] Jones NP(2013)Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study Diabetes Obes Metab 15 204-12

[7] Green J(2011)Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial Diabetes Obes Metab 13 81-8

[8] Feinglos M(2014)Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial Diabetes Care 37 1797-805

[9] Holst JJ(2013)Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus Intern Med 52 1029-34

[10] Knudsen LB(2014)Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin Eur J Endocrinol 170 451-9